Treatment for Diabetic Neuropathy Using Repetitive Transcranial Magnetic Stimulation
Launched by MCMASTER UNIVERSITY · Jun 26, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a treatment called repetitive transcranial magnetic stimulation (rTMS) to see if it can help relieve symptoms of diabetic neuropathy. Diabetic neuropathy is a condition that can cause pain, tingling, and numbness in the feet and hands due to nerve damage from diabetes. Over a period of four weeks, participants will receive rTMS and will be closely monitored using questionnaires, nerve tests, and blood tests to check for any improvements in their symptoms.
To be eligible for this study, participants must have a diagnosis of diabetic neuropathy. However, if someone has certain medical conditions that prevent them from safely receiving rTMS or if they have a psychological condition that makes it hard to understand the study, they won't be able to participate. This study is open to adults of all genders, and while it is not yet recruiting participants, it aims to help improve the lives of those suffering from this challenging condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A diagnosis of diabetic neuropathy
- Exclusion Criteria:
- • Contraindications to transcranial magnetic stimulation
- • Known psychological diagnosis affecting comprehension
- • Inability to participate in the study
About Mcmaster University
McMaster University, a leading research institution located in Hamilton, Ontario, Canada, is renowned for its innovative approach to education and its commitment to advancing healthcare through rigorous clinical research. The university's diverse research programs are supported by a multidisciplinary team of experts dedicated to improving patient outcomes and public health. With a strong emphasis on evidence-based medicine, McMaster University actively engages in clinical trials that explore new therapies, interventions, and health technologies, fostering collaboration among researchers, healthcare professionals, and industry partners to translate findings into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamilton, Ontario, Canada
Patients applied
Trial Officials
Aimee Nelson, PhD
Principal Investigator
McMaster University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported